Experts clarify that while reports of pancreatitis occurring after the use of GLP-1 agonists, such as semaglutide and liraglutide, have increased in Brazil, these cases remain rare. The Agência Nacional de Vigilância Sanitária (ANVISA) has noted a rise in suspicious reports between 2020 and 2025, with a total of six suspected deaths attributed to these weight-loss medications. Nevertheless, health professionals emphasize that there is no cause for excessive concern regarding the safety of these drugs.

The specific warning against the use of these medications is directed towards patients with a history of recurring pancreatitis, outlined in the product warnings for drugs like Mounjaro. Experts reiterate that patients with two or more episodes of pancreatic inflammation should avoid these medications, but they point out that such individuals are a small subset of the population. The overall perspective shared by the interviewed doctors is that monitoring and responsible medical supervision of GLP-1 agonists are crucial but the risks should not be overstated.

The article highlights the importance of ongoing medical oversight in the administration of these drugs, particularly as the market for weight-loss medications evolves. With weight management being a significant health issue, especially in Brazil, the conversation surrounding the use of GLP-1 agonists provides essential reassurance to patients and caution against unprescribed uses. The report serves to instill a balanced view of the risks versus benefits of these medications, as well as the importance of individualized patient care in reducing potential health risks associated with their use.